Akero Therapeutics Inc’s recently made public that its Officer Timothy Rolph acquired Company’s shares for reported $2.6 million on Oct 07 ’25. In the deal valued at $46.04 per share,56,369 shares were bought.
Then, Young Jonathan sold 12,500 shares, generating $596,978 in total proceeds. Upon selling the shares at $47.76, the Chief Operating Officer now owns 196,898 shares.
Before that, Young Jonathan sold 586 shares. Akero Therapeutics Inc shares valued at $25,210 were divested by the Chief Operating Officer at a price of $43.02 per share. As a result of the transaction, Young Jonathan now holds 196,898 shares, worth roughly $9.06 million.
A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early August with a ‘”a Buy”‘ rating. BofA Securities also remained covering AKRO and has increased its forecast on January 30, 2025 with a “Buy” recommendation from previously “Neutral” rating. H.C. Wainwright maintained its rating on January 27, 2025. It rated AKRO as “a Buy”.
Price Performance Review of AKRO
On Tuesday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -0.09% to $46.0. Over the last five days, the stock has lost -3.12%. Akero Therapeutics Inc shares have risen nearly 66.37% since the year began. Nevertheless, the stocks have risen 65.35% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $21.34 was recorded on 01/14/25.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 45.20, which if violated will result in even more drops to 44.40. On the upside, there is a resistance level at 47.10. A further resistance level may holdings at 48.20.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-09-15, dropping by -0.13 million shares to a total of 9.09 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 9.22 million shares. There was a decline of -1.41%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 18, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $65 price target.
